Question explored with the scientific record
is the hpv vaccine effective
The HPV vaccine substantially reduces the risk of cervical precancer and cancer, especially when given before exposure, but the evidence base is almost entirely manufacturer-funded and the long-term safety data is thin.
The strongest real-world evidence comes from England, where women offered the vaccine at age 12-13 had an 83.9% lower rate of invasive cervical cancer and a 94.3% lower rate of CIN3 (high-grade precancer) compared to unvaccinated cohorts [3]. A nationwide Japanese case-control study found vaccine effectiveness of about 81% against CIN3+ [1]. A 2025 systematic review reported a 63% reduction in any high-grade cervical lesion, including cross-protection against types not in the vaccine [2]. Anogenital wart incidence also dropped sharply after vaccine introduction in both females and males, consistent with herd protection [6].
| Outcome | Reduction in vaccinated vs unvaccinated | Source |
|---|---|---|
| Invasive cervical cancer (England, age 12-13 cohort) | 83.9% | [3] |
| CIN3 (England, age 12-13 cohort) | 94.3% | [3] |
| CIN3+ (Japan, age 20-24) | ~81% | [1] |
| Any high-grade cervical lesion (Cochrane meta-analysis) | 63% | [2] |
The benefit is clearest for those vaccinated before HPV exposure. Effectiveness drops sharply with older age at vaccination: a 97% reduction in CIN3 for the 12-13 cohort versus 39% for the 16-18 cohort [2]. One long-term follow-up study reported a concerning signal of "clinical unmasking" (more disease from non-vaccine types), though other studies found cross-protection instead [2]. The evidence does not include a single large, independently funded, long-term safety trial comparing vaccinated to unvaccinated people. The early pivotal trials were all funded by the manufacturers (Merck and GSK) [4, 5]. Passive surveillance systems like VAERS detect only a fraction of adverse events by design.
My call: the vaccine is effective at preventing HPV infections and their downstream cancers, especially in pre-adolescents, but the safety data is weaker than the efficacy data and the evidence base is industry-funded. Confidence: moderate.
Sources used 6
-
Human papillomavirus vaccine to prevent cervical intraepithelial neoplasia in Japan: A nationwide case‐control study
A nationwide Japanese case-control study showing that HPV vaccination substantially reduces the risk of abnormal cytology and cervical intraepithelial neoplasia (CIN1+, CIN2+, CIN3+) among women aged 20–24, with vaccine effectiveness up to about 81% for CIN3+ and ~59% for CIN1+.
DOI: 10.1111/cas.14682 -
The Impact of Prophylactic HPV Vaccination on the Incidence of High-Grade Cervical Intraepithelial Neoplasia (CIN2/CIN3): A Systematic Review
This systematic review finds HPV vaccination provides substantial protection against cervical precancer/cancer, with evidence for one-dose schedules, cross-protection, and reduced effectiveness with older vaccination; findings are promising but mixed and do not challenge the ove…
DOI: 10.70070/kjmnzx32 -
Effect of the HPV vaccination programme on incidence of cervical cancer and grade 3 cervical intraepithelial neoplasia by socioeconomic deprivation in England: population based observational study
In England, the HPV vaccination programme remained highly effective in July 2019-June 2020 and reduced cervical cancer and CIN3 incidence across all five socioeconomic deprivation fifths, flattening the cervical cancer deprivation gradient among vaccine-offered cohorts.
DOI: 10.1136/bmj-2023-077341 -
HPV Vaccines
Prophylactic HPV vaccines based on virus-like particles (types 6/11/16/18 and 16/18) show high efficacy against persistent HPV infections and related cervical lesions in randomized trials, supporting vaccination before HPV exposure while highlighting implementation challenges an…
DOI: 10.1097/00256406-200606300-00001 -
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
This study demonstrates that a prophylactic quadrivalent HPV vaccine significantly reduces the incidence of infections and diseases associated with HPV types 6, 11, 16, and 18 in young women.
DOI: 10.1016/s1470-2045(05)70101-7 -
Temporal Trends in the Incidence of Anogenital Warts: Impact of Human Papillomavirus Vaccination
In a retrospective ecologic interrupted time-series analysis of Kaiser Permanente Northwest enrollees aged 11-39, anogenital wart incidence declined in females and males after HPV vaccine introduction, reversing pre-vaccine increasing trends despite suboptimal three-dose coverag…
DOI: 10.1097/olq.0000000000001103